GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » Forward PE Ratio

Nanoform Finland (OSTO:NANOFS) Forward PE Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Forward PE Ratio?

Nanoform Finland's Forward PE Ratio for today is 0.00.

Nanoform Finland's PE Ratio without NRI for today is 0.00.

Nanoform Finland's PE Ratio for today is 0.00.


Nanoform Finland Forward PE Ratio Historical Data

The historical data trend for Nanoform Finland's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Forward PE Ratio Chart

Nanoform Finland Annual Data
Trend
Forward PE Ratio

Nanoform Finland Quarterly Data
Forward PE Ratio

Competitive Comparison of Nanoform Finland's Forward PE Ratio

For the Biotechnology subindustry, Nanoform Finland's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Forward PE Ratio falls into.



Nanoform Finland Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Nanoform Finland  (OSTO:NANOFS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Nanoform Finland Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland (OSTO:NANOFS) Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines